U.S. To Assign 15 FDA Inspectors To China In October
This article was originally published in PharmAsia News
The U.S. government plans to assign as many as 15 inspectors to three major cities in China, beginning in October, to conduct U.S. FDA inspections of drug and other regulated products. In an interview, Michael Leavitt, secretary of Health and Human Services, said China still has not solved all the problems it had with safety of items made for export to the United States, but "they moved aggressively to begin making progress." The first inspectors are to be placed in Beijing, Shanghai and Guangzhou, Leavitt said, but added he does not expect many future problems with Chinese-made drugs and other products. (Click here for more
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.